{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T03:14:36Z","timestamp":1780542876189,"version":"3.54.1"},"reference-count":213,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.intimp.2025.115432","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T15:31:22Z","timestamp":1756654282000},"page":"115432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Stem-like CD4+ T cells mediate T-cell state transitions to enhance tumor control and immunotherapy response"],"prefix":"10.1016","volume":"165","author":[{"given":"Mamali","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandramohan","family":"Kiruthiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nachammai","family":"Kathiresan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipali","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrabose","family":"Selvaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Langeswaran","family":"Kulanthaivel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.115432_bb0005","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2025.115432_bb0010","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41573-021-00155-y","article-title":"Beyond immune checkpoint blockade: emerging immunological strategies","volume":"20","author":"Kubli","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2025.115432_bb0015","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1016\/j.apsb.2021.03.004","article-title":"Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development","volume":"11","author":"Wang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.intimp.2025.115432_bb0020","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/s41416-021-01353-6","article-title":"Promises and challenges of adoptive T-cell therapies for solid tumours","volume":"124","author":"Morotti","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2025.115432_bb0025","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41590-023-01682-z","article-title":"CD4+ T cell immunity is dependent on an intrinsic stem-like program","volume":"25","author":"Zou","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0030","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to Cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.115432_bb0035","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028480","article-title":"Interferon \u03b3 and its important roles in promoting and inhibiting spontaneous and therapeutic Cancer immunity","volume":"11","author":"Alspach","year":"2019","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.intimp.2025.115432_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1327717","article-title":"Metabolic reprogramming in the tumor microenvironment: unleashing T cell stemness for enhanced cancer immunotherapy","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115432_bb0045","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13046-022-02273-w","article-title":"Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy","volume":"41","author":"Liu","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.115432_bb0050","article-title":"Predicting durable responses to immune checkpoint inhibitors in non-small-cell lung Cancer using a multi-feature model","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.754768","article-title":"First-line treatment options for PD-L1\u2013negative non-small cell lung Cancer: a Bayesian network Meta-analysis","volume":"11","author":"Peng","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2025.115432_bb0060","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115432_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113797","article-title":"Stem-like progenitor and terminally differentiated TFH-like CD4+ T cell exhaustion in the tumor microenvironment","volume":"43","author":"Zhou","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2025.115432_bb0070","article-title":"Characteristics of T-cell receptor repertoire of stem cell-like memory CD4+ T cells","volume":"9","author":"Wang","year":"2021","journal-title":"PeerJ"},{"key":"10.1016\/j.intimp.2025.115432_bb0075","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.3390\/ijms24054326","article-title":"TCF-1 is required for CD4 T cell persistence functions during AlloImmunity","volume":"24","author":"Mammadli","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115432_bb0080","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1111\/cas.13648","article-title":"Generation and application of human induced-stem cell memory T cells for adoptive immunotherapy","volume":"109","author":"Kondo","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.intimp.2025.115432_bb0085","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/JLB.5MR0321-145R","article-title":"Stem cell-like memory T cells: the generation and application","volume":"110","author":"Wang","year":"2021","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2025.115432_bb0090","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abb9726","article-title":"T cell factor 1: a master regulator of the T cell response in disease","volume":"5","author":"Escobar","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0095","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/imr.12705","article-title":"<scp>JAK<\/scp> \/ <scp>STAT<\/scp> signaling in regulation of innate lymphoid cells: the gods before the guardians","volume":"286","author":"Stabile","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2025.115432_bb0100","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ncomms2260","article-title":"T-bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-specific targeting of distal regulatory elements","volume":"3","author":"Kanhere","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115432_bb0105","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1158\/1541-7786.MCR-22-0567","article-title":"B-cell lymphoma 6 (BCL6): from Master regulator of humoral immunity to oncogenic driver in pediatric cancers","volume":"20","author":"McLachlan","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.intimp.2025.115432_bb0110","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)00020-0","article-title":"BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control","volume":"13","author":"Shaffer","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.115432_bb0115","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/ni.3226","article-title":"LEF-1 and TCF-1 orchestrate T(FH) differentiation by regulating differentiation circuits upstream of the transcriptional repressor Bcl6","volume":"16","author":"Choi","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00016","article-title":"Memory T follicular helper CD4 T cells","volume":"6","author":"Hale","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0125","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-immunol-031210-101400","article-title":"Follicular helper CD4 T cells (T FH)","volume":"29","author":"Crotty","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","article-title":"T cells in health and disease","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2025.115432_bb0135","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.micinf.2009.04.007","article-title":"Signal transduction and Th17 cell differentiation","volume":"11","author":"O\u2019Shea","year":"2009","journal-title":"Microbes Infect."},{"key":"10.1016\/j.intimp.2025.115432_bb0140","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.smim.2007.10.011","article-title":"Transcriptional regulation of Th17 cell differentiation","volume":"19","author":"Ivanov","year":"2007","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.imlet.2022.05.001","article-title":"CD4+ cytotoxic T cells \u2013 phenotype, function and transcriptional networks controlling their differentiation pathways","volume":"247","author":"Preglej","year":"2022","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.intimp.2025.115432_bb0150","doi-asserted-by":"crossref","first-page":"200","DOI":"10.15698\/cst2018.07.148","article-title":"T lymphocytes against solid malignancies: winning ways to defeat tumours","volume":"2","author":"Caruana","year":"2018","journal-title":"Cell Stress"},{"key":"10.1016\/j.intimp.2025.115432_bb0155","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.210.Supp.86.04","article-title":"Stem-like CD4 T differentiation controls CD8 T cell immunity or tolerance in cancer","volume":"210","author":"Cardenas","year":"2023","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00194","article-title":"CD4 CTL, a cytotoxic subset of CD4+ T cells, their differentiation and function","volume":"8","author":"Takeuchi","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0165","doi-asserted-by":"crossref","DOI":"10.1093\/oxfimm\/iqad006","article-title":"The current state and future of T-cell exhaustion research","volume":"4","author":"Jenkins","year":"2023","journal-title":"Oxford Open Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0170","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.trecan.2022.04.004","article-title":"Mechanisms of T cell exhaustion guiding next-generation immunotherapy","volume":"8","author":"Zebley","year":"2022","journal-title":"Trends in Cancer."},{"key":"10.1016\/j.intimp.2025.115432_bb0175","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115432_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00491","article-title":"A threshold model for T-cell activation in the era of checkpoint blockade immunotherapy","volume":"10","author":"Guram","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.907172","article-title":"Stem-like T cells and niches: implications in human health and disease","volume":"13","author":"Yi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0190","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.2147\/OTT.S150817","article-title":"Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer","volume":"11","author":"Grywalska","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.intimp.2025.115432_bb0195","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.1229620","article-title":"Progenitor and terminal subsets of CD8 + T cells cooperate to contain chronic viral infection","volume":"338","author":"Paley","year":"2012","journal-title":"Science (80-.)"},{"key":"10.1016\/j.intimp.2025.115432_bb0200","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2567.2010.03255.x","article-title":"T-cell exhaustion: characteristics, causes and conversion","volume":"129","author":"Yi","year":"2010","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2025.115432_bb0205","article-title":"CXCL13 in Cancer and Other Diseases: Biological Functions, Clinical Significance, and Therapeutic Opportunities","volume":"vol. 11","author":"Gao","year":"2021","journal-title":"Life (Basel, Switzerland)"},{"key":"10.1016\/j.intimp.2025.115432_bb0210","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.canlet.2024.217278","article-title":"Revisiting the CXCL13\/CXCR5 axis in the tumor microenvironment in the era of single-cell omics: implications for immunotherapy","volume":"605","author":"Gu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2025.115432_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/cells11172649","article-title":"The CXCL13\/CXCR5 immune Axis in health and disease-implications for intrathecal B cell activities in Neuroinflammation","volume":"11","author":"Harrer","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2025.115432_bb0220","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1172\/JCI67428","article-title":"CD4+ follicular helper T cell infiltration predicts breast cancer survival","volume":"123","author":"Gu-Trantien","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2025.115432_bb0225","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1091\/mbc.e05-07-0631","article-title":"Granule-mediated killing by granzyme B and perforin requires a mannose 6-phosphate receptor and is augmented by cell surface heparan sulfate","volume":"17","author":"Veugelers","year":"2006","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.intimp.2025.115432_bb0230","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adg3868","article-title":"Cellular and molecular waypoints along the path of T cell exhaustion","volume":"8","author":"Lan","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0235","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1104771","article-title":"T-cell exhaustion and stemness in antitumor immunity: characteristics, mechanisms, and implications","volume":"14","author":"Chi","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0245","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.390","article-title":"The role of CD4 + T cells in tumor and chronic viral immune responses","volume":"4","author":"Xie","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.intimp.2025.115432_bb0250","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.immuni.2021.11.015","article-title":"Cytotoxic CD4+ T cells in cancer: expanding the immune effector toolbox","volume":"54","author":"Oh","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.115432_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.951900","article-title":"When helpers go above and beyond: development and characterization of cytotoxic CD4+ T cells","volume":"13","author":"Hoeks","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0260","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2025.115432_bb0265","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0270","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.3390\/cancers14194875","article-title":"Oncogenic role of HMGB1 as An alarming in robust prediction of immunotherapy response in colorectal Cancer","volume":"14","author":"Lu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2025.115432_bb0275","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.907572","article-title":"Tissue-resident innate immune cell-based therapy: a cornerstone of immunotherapy strategies for Cancer treatment","volume":"10","author":"Bus\u00e0","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.intimp.2025.115432_bb0280","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.3390\/cells10092361","article-title":"The immune privilege of Cancer stem cells: a key to understanding tumor immune escape and therapy failure","volume":"10","author":"Galassi","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2025.115432_bb0285","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nm.1982","article-title":"Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells","volume":"15","author":"Gattinoni","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2025.115432_bb0290","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nri2251","article-title":"Shaping and reshaping CD8+ T-cell memory","volume":"8","author":"Harty","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0295","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.115432_bb0300","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2008-05-078154","article-title":"CD4 T cells: fates, functions, and faults","volume":"112","author":"Zhu","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2025.115432_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00001","article-title":"Murine Butyrophilin-like 1 and Btnl6 form Heteromeric complexes in small intestinal epithelial cells and promote proliferation of local T lymphocytes","volume":"7","author":"Lebrero-Fern\u00e1ndez","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0310","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.immuni.2007.08.007","article-title":"Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection","volume":"27","author":"Kaech","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.115432_bb0315","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0320","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the Cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.115432_bb0330","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.1038\/s41467-023-42455-4","article-title":"Interferon-\u03b3 couples CD8+ T cell avidity and differentiation during infection","volume":"14","author":"Uhl","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115432_bb0335","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.3390\/ijms23031833","article-title":"Granzymes: the molecular executors of immune-mediated cytotoxicity","volume":"23","author":"Hay","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115432_bb0340","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/gene.2014.45","article-title":"Regulatory T cells and immune regulation of allergic diseases: roles of IL-10 and TGF-\u03b2","volume":"15","author":"Palomares","year":"2014","journal-title":"Genes Immun."},{"key":"10.1016\/j.intimp.2025.115432_bb0345","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science (80-.)"},{"key":"10.1016\/j.intimp.2025.115432_bb0350","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.115432_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02293","article-title":"WNT\/\u03b2-catenin signaling pathway regulating T cell-inflammation in the tumor microenvironment","volume":"10","author":"Li","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0360","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.tips.2018.03.008","article-title":"Targeting Wnt\/\u03b2-catenin signaling for Cancer immunotherapy","volume":"39","author":"Wang","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.intimp.2025.115432_bb0365","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/ni.3288","article-title":"Control of peripheral tolerance by regulatory T cell\u2013intrinsic Notch signaling","volume":"16","author":"Charbonnier","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0370","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-023-01439-z","article-title":"The Notch signaling pathway: a potential target for cancer immunotherapy","volume":"16","author":"Li","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2025.115432_bb0375","doi-asserted-by":"crossref","DOI":"10.4161\/onci.29029","article-title":"Notch and TGF\u03b2","volume":"3","author":"Ohnuki","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2025.115432_bb0380","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/imr.12796","article-title":"mTOR and other effector kinase signals that impact T cell function and activity","volume":"291","author":"Myers","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2025.115432_bb0385","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nri3198","article-title":"Regulation and function of mTOR signalling in T cell fate decisions","volume":"12","author":"Chi","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0390","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.4161\/cc.9.15.12359","article-title":"Fine-tuning CD8 + T-cell functional responses: mTOR acts as a rheostat for regulating CD8 + T-cell proliferation, survival and differentiation?","volume":"9","author":"Rao","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.intimp.2025.115432_bb0395","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coi.2019.02.002","article-title":"Studying interactions between dendritic cells and T cells in vivo","volume":"58","author":"Chudnovskiy","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0400","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.immuni.2023.08.014","article-title":"Dendritic cells as shepherds of T cell immunity in cancer","volume":"56","author":"Pittet","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.115432_bb0405","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00569","article-title":"Tolerogenic dendritic cells for regulatory T cell induction in man","volume":"6","author":"Raker","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0410","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adg0878","article-title":"Sustained CD28 costimulation is required for self-renewal and differentiation of TCF-1 + PD-1 + CD8 T cells","volume":"8","author":"Humblin","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0415","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1213629","article-title":"Impaired function of dendritic cells within the tumor microenvironment","volume":"14","author":"Xiao","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0420","series-title":"No Title","year":"2025"},{"key":"10.1016\/j.intimp.2025.115432_bb0425","article-title":"Shaping polarization of tumor-associated macrophages in Cancer immunotherapy","volume":"13","author":"Gao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1160340","article-title":"Dynamic polarization of tumor-associated macrophages and their interaction with intratumoral T cells in an inflamed tumor microenvironment: from mechanistic insights to therapeutic opportunities","volume":"14","author":"Han","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0435","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.590941","article-title":"The crosstalk between tumor-associated macrophages (TAMs) and tumor cells and the corresponding targeted therapy","volume":"10","author":"Ge","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2025.115432_bb0440","article-title":"Tumor-associated macrophages: recent insights and therapies","volume":"10","author":"Zhou","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2025.115432_bb0445","doi-asserted-by":"crossref","first-page":"27548","DOI":"10.1038\/srep27548","article-title":"M2-polarized macrophages contribute to neovasculogenesis, leading to relapse of oral cancer following radiation","volume":"6","author":"Okubo","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2025.115432_bb0450","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00219","article-title":"Cognate interaction with CD4+ T cells instructs tumor-associated macrophages to acquire M1-like phenotype","volume":"10","author":"Eisel","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0455","doi-asserted-by":"crossref","first-page":"7493","DOI":"10.3390\/ijms24087493","article-title":"Tumor-associated macrophage subsets: shaping polarization and targeting","volume":"24","author":"Zhang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115432_bb0460","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.immuni.2008.11.002","article-title":"Homeostasis of naive and memory T cells","volume":"29","author":"Surh","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.115432_bb0465","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.exphem.2016.06.003","article-title":"IL-2, IL-7, and IL-15: multistage regulators of CD4+ T helper cell differentiation","volume":"44","author":"Read","year":"2016","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.intimp.2025.115432_bb0470","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035572","article-title":"Inflammation-driven reprogramming of CD4+Foxp3+ regulatory T cells into pathogenic Th1\/Th17 T effectors is abrogated by mTOR inhibition in vivo","volume":"7","author":"Yurchenko","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2025.115432_bb0475","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.669474","article-title":"Differentiation and regulation of TH cells: a balancing act for Cancer immunotherapy","volume":"12","author":"Basu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0480","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.it.2005.01.004","article-title":"IL-7: maintaining T-cell memory and achieving homeostasis","volume":"26","author":"Bradley","year":"2005","journal-title":"Trends Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0485","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.4049\/jimmunol.0903151","article-title":"IL-7 promotes T cell viability, trafficking, and functionality and improves survival in Sepsis","volume":"184","author":"Unsinger","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0490","doi-asserted-by":"crossref","DOI":"10.4110\/in.2024.24.e11","article-title":"IL-15 in T-cell responses and Immunopathogenesis","volume":"24","author":"Lee","year":"2024","journal-title":"Immune Netw."},{"key":"10.1016\/j.intimp.2025.115432_bb0495","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1158\/0008-5472.CAN-15-1498","article-title":"IL15 and T-cell Stemness in T-cell\u2013based Cancer immunotherapy","volume":"75","author":"Pilipow","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2025.115432_bb0500","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.molimm.2019.11.011","article-title":"Control of memory CD8+ T cell longevity and effector functions by IL-15","volume":"117","author":"Nolz","year":"2020","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0505","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cmet.2006.01.012","article-title":"HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption","volume":"3","author":"Papandreou","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.intimp.2025.115432_bb0510","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/ijc.29519","article-title":"HIF-1 at the crossroads of hypoxia, inflammation, and cancer","volume":"138","author":"Balamurugan","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2025.115432_bb0515","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115432_bb0520","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1577081","article-title":"Impact of mitochondrial metabolism on T-cell dysfunction in chronic lymphocytic leukemia","volume":"13","author":"Gamal","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.intimp.2025.115432_bb0525","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","article-title":"FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy","volume":"629","author":"Chan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.115432_bb0530","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1016\/j.cell.2024.08.029","article-title":"Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy","volume":"187","author":"Baldwin","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.115432_bb0535","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41419-022-05194-w","article-title":"Zeb1 sustains hematopoietic stem cell functions by suppressing mitofusin-2-mediated mitochondrial fusion","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2025.115432_bb0540","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1186\/s12967-025-06472-9","article-title":"Therapeutic implications of mitochondrial transfer on stem cell fate in regenerative medicine","volume":"23","author":"Liu","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2025.115432_bb0545","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cmet.2015.11.002","article-title":"Mitochondrial membrane potential identifies cells with enhanced Stemness for cellular therapy","volume":"23","author":"Sukumar","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.intimp.2025.115432_bb0550","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1340702","article-title":"Crosstalk between T lymphocyte and extracellular matrix in tumor microenvironment","volume":"15","author":"Lv","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0555","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00073","article-title":"Tumor microenvironment-associated extracellular matrix components regulate NK cell function","volume":"11","author":"Rossi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0560","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/2326-6066.CIR-20-0070","article-title":"Immune remodeling of the extracellular matrix drives loss of Cancer stem cells and tumor rejection","volume":"8","author":"Pires","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2025.115432_bb0565","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","article-title":"Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments","volume":"22","author":"Yuan","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2025.115432_bb0570","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/cancers14010238","article-title":"The functional role of extracellular matrix proteins in Cancer","volume":"14","author":"Popova","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2025.115432_bb0575","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.791453","article-title":"Immune modulatory properties of collagen in Cancer","volume":"12","author":"R\u00f8mer","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0580","article-title":"Targeting collagen in \u201carmored & cold\u201d tumors: Overcoming barriers to cancer therapy","author":"Wang","year":"2024","journal-title":"Cancer Pathog. Ther."},{"key":"10.1016\/j.intimp.2025.115432_bb0585","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1340634","article-title":"Extracellular matrix remodeling in the tumor immunity","volume":"14","author":"Du","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0590","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2025.115432_bb0595","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2217\/ahe.11.56","article-title":"The aging immune system and its relationship with Cancer","volume":"7","author":"Foster","year":"2011","journal-title":"Aging Health"},{"key":"10.1016\/j.intimp.2025.115432_bb0600","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1348189","article-title":"Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients","volume":"15","author":"Al-Danakh","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0605","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.trecan.2022.06.007","article-title":"Age-associated differences in the cancer molecular landscape","volume":"8","author":"Chatsirisupachai","year":"2022","journal-title":"Trends in Cancer."},{"key":"10.1016\/j.intimp.2025.115432_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116401","article-title":"Engineering a long acting, non-biased relaxin agonist using protein-in-protein technology","volume":"227","author":"Agoulnik","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115432_bb0615","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2013.00193","article-title":"Strategies to increase drug penetration in solid tumors","volume":"3","author":"Choi","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2025.115432_bb0620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/biores.2013.0047","article-title":"BRG1 is required to maintain pluripotency of murine embryonic stem cells","volume":"3","author":"Singhal","year":"2014","journal-title":"Biores. Open Access"},{"key":"10.1016\/j.intimp.2025.115432_bb0625","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1038\/s41467-021-25107-3","article-title":"OCT4 cooperates with distinct ATP-dependent chromatin remodelers in na\u00efve and primed pluripotent states in human","volume":"12","author":"Huang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115432_bb0630","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1042\/BST20230416","article-title":"The SWI\/SNF ATP-dependent chromatin remodeling complex in cell lineage priming and early development","volume":"52","author":"Saha","year":"2024","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.intimp.2025.115432_bb0635","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1182\/blood-2023-187411","article-title":"CPT1a controls the function of long-term hematopoietic stem cells by regulating the balance between fatty acid oxidation and Oxphos in mitochondria","volume":"142","author":"Hashimoto","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2025.115432_bb0640","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/imr.12655","article-title":"Fatty acid metabolism in <scp>CD<\/scp> 8 + T cell memory: challenging current concepts","volume":"283","author":"Raud","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2025.115432_bb0645","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184069","article-title":"Loss of Cpt1a results in elevated glucose-fueled mitochondrial oxidative phosphorylation and defective hematopoietic stem cells","volume":"135","author":"Li","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2025.115432_bb0650","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1242\/dev.058230","article-title":"An emerging role for TOR signaling in mammalian tissue and stem cell physiology","volume":"138","author":"Russell","year":"2011","journal-title":"Development"},{"key":"10.1016\/j.intimp.2025.115432_bb0655","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ebiom.2016.01.019","article-title":"Modulation of mTOR Signalling triggers the formation of stem cell-like memory T cells","volume":"4","author":"Scholz","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2025.115432_bb0660","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2024.1611643","article-title":"mTOR hyperactivity and RICTOR amplification as targets for personalized treatments in malignancies","volume":"30","author":"Sztankovics","year":"2024","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.intimp.2025.115432_bb0665","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science (80-.)"},{"key":"10.1016\/j.intimp.2025.115432_bb0670","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.115432_bb0675","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cell.2020.06.013","article-title":"Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma","volume":"182","author":"Gillette","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.115432_bb0680","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1182\/bloodadvances.2018016279","article-title":"TCF1 expression marks self-renewing human CD8+ T cells","volume":"2","author":"Kratchmarov","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2025.115432_bb0685","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","article-title":"Differentiation of effector CD4 T cell populations","volume":"28","author":"Zhu","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0690","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1426418","article-title":"Stem-like CD8+ T cells in cancer","volume":"15","author":"Steiner","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0695","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.115432_bb0700","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1158\/1078-0432.CCR-21-0206","article-title":"CD4 T-cell exhaustion: does it exist and what are its roles in Cancer?","volume":"27","author":"Miggelbrink","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.115432_bb0705","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1126\/science.abb9847","article-title":"Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer","volume":"370","author":"Krishna","year":"2020","journal-title":"Science (80-.)"},{"key":"10.1016\/j.intimp.2025.115432_bb0710","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.115432_bb0715","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41590-023-01543-9","article-title":"Neoantigen-specific stem cell memory-like CD4+ T cells mediate CD8+ T cell-dependent immunotherapy of MHC class II-negative solid tumors","volume":"24","author":"Brightman","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0720","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ccell.2022.02.004","article-title":"Stem-cell-like T cells have a specific entry gate to the tumor","volume":"40","author":"Held","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.115432_bb0725","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s41590-022-01219-w","article-title":"\u2018Stem-like\u2019 precursors are the fount to sustain persistent CD8+ T cell responses","volume":"23","author":"Zehn","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0730","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.115432_bb0735","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.115432_bb0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109078","article-title":"Stem cell like memory T cells: a new paradigm in cancer immunotherapy","volume":"241","author":"Wang","year":"2022","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0745","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01718","article-title":"NOTCH signaling in T-cell-mediated anti-tumor immunity and T-cell-based immunotherapies","volume":"9","author":"Kelliher","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0750","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nm.4241","article-title":"T memory stem cells in health and disease","volume":"23","author":"Gattinoni","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2025.115432_bb0755","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1158\/2326-6066.CIR-17-0016","article-title":"The antitumor effects of vaccine-activated CD8+ T cells associate with weak TCR signaling and induction of stem-like memory T cells","volume":"5","author":"Wu","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2025.115432_bb0760","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41590-020-00810-3","article-title":"Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells","volume":"22","author":"Baharom","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0765","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41416-023-02181-6","article-title":"Immune checkpoint inhibitor combinations\u2014current and emerging strategies","volume":"128","author":"Walsh","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2025.115432_bb0770","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.115432_bb0775","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2025.115432_bb0780","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in Cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.intimp.2025.115432_bb0785","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.3390\/jcm12134301","article-title":"Review of the immune checkpoint inhibitors in the context of Cancer treatment","volume":"12","author":"Alturki","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.intimp.2025.115432_bb0790","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to Cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.115432_bb0795","doi-asserted-by":"crossref","first-page":"7371","DOI":"10.1182\/blood-2022-167601","article-title":"Overcoming CD19-negative relapses in patients with B-cell lymphomas treated with Tisagenlecleucel","volume":"140","author":"Ghilardi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2025.115432_bb0800","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation Cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.115432_bb0805","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","article-title":"CAR-T therapies in solid tumors: opportunities and challenges","volume":"25","author":"Guzman","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.intimp.2025.115432_bb0810","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.intimp.2025.115432_bb0815","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science (80-.)"},{"key":"10.1016\/j.intimp.2025.115432_bb0820","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1016\/j.jtho.2016.11.236","article-title":"OA02.06 converting tumor-mediated PD-L1 inhibition into CAR T-cell Costimulation to potentiate thoracic cancers immunotherapy","volume":"12","author":"Morello","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.intimp.2025.115432_bb0825","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3390\/cells9071727","article-title":"Modulation of determinant factors to improve therapeutic combinations with immune checkpoint inhibitors","volume":"9","author":"Dosset","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2025.115432_bb0830","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41568-023-00615-0","article-title":"Stem-like exhausted and memory CD8+ T cells in cancer","volume":"23","author":"Gebhardt","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2025.115432_bb0835","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2025.115432_bb0840","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40164-024-00535-1","article-title":"Fueling CARs: metabolic strategies to enhance CAR T-cell therapy","volume":"13","author":"Van der Vreken","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2025.115432_bb0845","doi-asserted-by":"crossref","DOI":"10.1172\/JCI160025","article-title":"mTOR regulates T cell exhaustion and PD-1\u2013targeted immunotherapy response during chronic viral infection","volume":"133","author":"Ando","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2025.115432_bb0850","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.878209","article-title":"CAR-T cell performance: how to improve their persistence?","volume":"13","author":"L\u00f3pez-Cantillo","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0855","article-title":"CAR-T cell therapy for hematological malignancies: history, status and promise","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.intimp.2025.115432_bb0860","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1182\/blood.2022016226","article-title":"CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights","volume":"140","author":"Ali","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2025.115432_bb0865","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2300366120","article-title":"Targeted glycan degradation potentiates cellular immunotherapy for solid tumors","volume":"120","author":"Wu","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2025.115432_bb0870","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2025.115432_bb0875","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1113882","article-title":"The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies","volume":"14","author":"Daei Sorkhabi","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104112","article-title":"Combined antitumor effects of anti-EGFR variant III CAR-T cell therapy and PD-1 checkpoint blockade on glioblastoma in mouse model","volume":"352","author":"Song","year":"2020","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0885","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1190379","article-title":"Cytokine release syndrome and cancer immunotherapies \u2013 historical challenges and promising futures","volume":"14","author":"Shah","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0890","doi-asserted-by":"crossref","first-page":"6","DOI":"10.6004\/jnccn.2023.5033","article-title":"Navigating the challenges: effective Management of Toxicities in CAR T-cell therapies","volume":"21","author":"Oluwole","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.intimp.2025.115432_bb0895","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol. Ther. - Oncolytics."},{"key":"10.1016\/j.intimp.2025.115432_bb0900","first-page":"1","article-title":"Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review","volume":"20","author":"Li","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.intimp.2025.115432_bb0905","article-title":"Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy","volume":"21","author":"Zhang","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.intimp.2025.115432_bb0910","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01217","article-title":"Next-generation manufacturing protocols enriching TSCM CAR T cells can overcome disease-specific T cell defects in Cancer patients","volume":"11","author":"Arcangeli","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0915","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s13238-019-0643-y","article-title":"Chimeric antigen receptor T (CAR-T) cells expanded with IL-7\/IL-15 mediate superior antitumor effects","volume":"10","author":"Zhou","year":"2019","journal-title":"Protein Cell"},{"key":"10.1016\/j.intimp.2025.115432_bb0920","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40364-022-00434-9","article-title":"Strategies to enhance CAR-T persistence","volume":"10","author":"Liu","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.intimp.2025.115432_bb0925","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.immuni.2016.07.008","article-title":"Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8 + T cell exhaustion","volume":"45","author":"Bengsch","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.115432_bb0930","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-022-01255-x","article-title":"Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells","volume":"15","author":"Huang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2025.115432_bb0935","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jcyt.2025.05.010","article-title":"The next innovations in chimeric antigen receptor T cell immunotherapies for cancer","volume":"27","author":"Anupindi","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.intimp.2025.115432_bb0940","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142030","article-title":"Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes","volume":"131","author":"Roselli","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2025.115432_bb0945","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1016\/j.ymthe.2022.06.006","article-title":"Universal allogeneic CAR T cells engineered with sleeping beauty transposons and CRISPR-CAS9 for cancer immunotherapy","volume":"30","author":"Tipanee","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2025.115432_bb0950","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-019-0763-0","article-title":"Engineering switchable and programmable universal CARs for CAR T therapy","volume":"12","author":"Liu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2025.115432_bb0955","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.744823","article-title":"Advances in universal CAR-T cell therapy","volume":"12","author":"Lin","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0960","article-title":"Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input","volume":"15","author":"Wang","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2025.115432_bb0965","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.molmed.2017.03.002","article-title":"CARs: synthetic Immunoreceptors for Cancer therapy and beyond","volume":"23","author":"Chang","year":"2017","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.intimp.2025.115432_bb0970","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.coi.2019.04.009","article-title":"Remembering to remember: T cell memory maintenance and plasticity","volume":"58","author":"Omilusik","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0975","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.115432_bb0980","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","article-title":"Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion","volume":"22","author":"Scharping","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0985","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.immuni.2010.08.002","article-title":"Differentiation and persistence of memory CD8+ T cells depend on T cell factor 1","volume":"33","author":"Zhou","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.115432_bb0990","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb0995","article-title":"The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115432_bb1000","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1007\/s00415-020-10237-3","article-title":"Neurological updates: neurological complications of CAR-T therapy","volume":"268","author":"Tallantyre","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.intimp.2025.115432_bb1005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115432_bb1010","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2025.115432_bb1015","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2025.115432_bb1020","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.115432_bb1025","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2025.115432_bb1030","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115432_bb1035","doi-asserted-by":"crossref","first-page":"300","DOI":"10.7150\/thno.104594","article-title":"Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies","volume":"15","author":"Lin","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2025.115432_bb1040","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.115432_bb1045","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2025.115432_bb1050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejca.2022.07.004","article-title":"TCF1+PD-1+ tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer","volume":"174","author":"Koh","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.intimp.2025.115432_bb1055","doi-asserted-by":"crossref","first-page":"S866","DOI":"10.1016\/j.annonc.2024.08.1435","article-title":"1380P PK\/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: the PIONeeR trial","volume":"35","author":"Ciccolini","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2025.115432_bb1060","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_390290","article-title":"Immune resistance mechanisms and the road to personalized immunotherapy","author":"Piper","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. B."},{"key":"10.1016\/j.intimp.2025.115432_bb1065","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"National comprehensive cancer network, management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925014237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925014237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T15:11:21Z","timestamp":1763046681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925014237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":213,"alternative-id":["S1567576925014237"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115432","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stem-like CD4+ T cells mediate T-cell state transitions to enhance tumor control and immunotherapy response","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115432"}}